{"id":1707,"date":"2023-07-24T12:00:47","date_gmt":"2023-07-24T04:00:47","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&#038;p=1707"},"modified":"2025-11-10T16:31:58","modified_gmt":"2025-11-10T08:31:58","slug":"hanchorbio-announces-taiwan-fda-ind-approval-for-the-multi-regional-clinical-trial-of-hcb101-to-treat-solid-and-hematological-malignancies","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-announces-taiwan-fda-ind-approval-for-the-multi-regional-clinical-trial-of-hcb101-to-treat-solid-and-hematological-malignancies\/","title":{"rendered":"HANCHORBIO ANNOUNCES TAIWAN FDA IND APPROVAL FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.<\/p>\n","protected":false},"featured_media":0,"template":"","news-category":[],"class_list":["post-1707","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/1707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=1707"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=1707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}